Infiltrating T cells are found in many malignancies, but they appear to be mostly anergic and
do not attack the tumor, presumably because of the absence of activation and/or …

We previously constructed a humanized anti‐p185HER2/anti‐CD3 bispecific antibody
variant, BsF (ab′) 2 v1 which retargets the cytotoxic activity of human T cells in vitro against …

Antibody genes can now be cloned and expressed in various ways to give new versions of
antibodies that possess reduced immunogenicity, improved affinity, altered size, increased …

A cancer immunotherapy strategy is described herein that combines the advantage of the
well established tumor targeting capabilities of high-affinity recombinant fragments of Abs …

To investigate the mechanisms underlying the deficiency of T lymphocytes from patients with
Hodgkin's disease, we investigated the expression of the T-cell receptor (TCR) zeta chain in …

Bispecific antibodies directed against tumour associated antigens and the T cell receptor
component CD3 for recruitment and tumour targeted activation of T cells represent a novel …

Bispecific antibody (BsAb) technology has been successfully used as a means to construct
novel antibody (Ab) molecules with increased avidity for binding, by combining two Ab or …

Immunotherapy is a powerful anti-cancer treatment modality. However, despite numerous
encouraging results obtained in pre-clinical studies, a definite breakthrough towards an …

The arming of activated T cells (ATC) with BiAbs can overcome major barriers for successful
adoptive immunotherapy. The BiAb approach takes the advantage of the targeting specificity …

Trifunctional antibodies are able to redirect T cells and Fcγ receptor+ accessory immune
cells to tumor targets. The simultaneous activation of these different classes of effector cells …